Compare Crown Castle International Corp (CCI) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Inovio Pharmaceuticals Inc — how do they compare? Crown Castle International Corp trades at $74.09 (market cap $31.33B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Crown Castle International Corp is far larger — about 398.9× Inovio Pharmaceuticals Inc's market cap, and Crown Castle International Corp pays a 5.77% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CCI | INO | |
|---|---|---|
Market Cap | $31.33B | $78.55M |
Sector | Real Estate | Health |
52-Week High | $103.79 | $2.87 |
52-Week Low | $73.61 | $0.66 |
Enterprise Value | $53.69B | $49.56M |
Dividend Yield | 5.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $73.61, down 2.62% on the day and near 52-week lows. The technical picture is bearish with mixed fundamentals - strong profitability margins (73.7% gross margin) but negative shareholder equity and high debt levels. Recent Q2 2026 earnings beat expectations with AFFO of $1.13 per share, while the company transitions to a pure-play U.S. tower operator following asset sales.
The stock presents a contrarian opportunity with 50% analyst buy ratings and a $95.29 price target suggesting 29% upside, but faces significant debt burden and execution risks from strategic shifts. The 5.5% dividend yield provides income support while investors await operational improvements.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
